<DOC>
	<DOC>NCT00430261</DOC>
	<brief_summary>This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.</brief_summary>
	<brief_title>Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma</brief_title>
	<detailed_description>To participate in this study, patients must have disease that can be measured on a CT scan. Brain metastases are OK if stable. Pregnant and/or nursing women may not participate. This drug has been approved by the FDA for the treatment of advanced renal cell cancer and a certain type of stomach/intestinal cancer. Its efficacy in lung cancer in currently unknown. Common side effects include fatigue, nausea, diarrhea, skin reaction, and decreased blood counts.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Adenocarcinoma, Bronchiolo-Alveolar</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Bronchoalveolar carcinoma with disease measurable on CAT scan Any lung adenocarcinoma in a neversmoker (less than 100 cigarettes lifetime) with disease measurable on CAT scan Stage IIIB or IV Uncontrolled hypertension Unstable brain metastases Pregnant/nursing women Uncontrolled thyroid disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>bronchoalveolar carcinoma</keyword>
	<keyword>BAC</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>lung cancer</keyword>
	<keyword>oral</keyword>
	<keyword>Stage IIIB and IV lung cancer</keyword>
	<keyword>Any bronchoalveolar carcinoma (BAC)</keyword>
	<keyword>Any adenocarcinoma in a never-smoker</keyword>
</DOC>